【摘要】：醫(yī)藥制造業(yè)是涉及國民健康、社會穩(wěn)定和經濟發(fā)展的重要產業(yè)，也是世界上發(fā)展最快、競爭最為激烈的產業(yè)之一。隨著經濟開放化進程的加快，如何有效提升醫(yī)藥制造業(yè)企業(yè)創(chuàng)新能力，提高企業(yè)績效，保持企業(yè)持續(xù)發(fā)展，這無疑是當今企業(yè)急需關注和解決的重要問題。研究醫(yī)藥制造業(yè)企業(yè)創(chuàng)新能力與績效的關系，不僅對企業(yè)發(fā)展具有指導意義，而且對政府制定相關政策具有參考作用。 本文采用理論與實證相結合的分析方法，首先根據國內外關于企業(yè)創(chuàng)新能力與績效的相關文獻及理論知識，界定了企業(yè)創(chuàng)新能力內涵及醫(yī)藥制造業(yè)企業(yè)創(chuàng)新能力的構成要素，闡述了醫(yī)藥制造業(yè)企業(yè)創(chuàng)新能力構成要素即市場營銷創(chuàng)新能力、管理創(chuàng)新能力、技術創(chuàng)新能力、制度創(chuàng)新能力這四要素的內在關系及各要素對企業(yè)績效的作用機理；其次，基于醫(yī)藥制造業(yè)發(fā)展狀況及行業(yè)特征，選取上交所36家醫(yī)藥制造業(yè)樣本企業(yè)，構建了醫(yī)藥制造業(yè)上市公司創(chuàng)新能力評價指標體系。并采用因子分析法分析得到醫(yī)藥制造業(yè)上市公司創(chuàng)新能力整體水平不高，企業(yè)之間創(chuàng)新能力差距較大，，應加強創(chuàng)新能力的培育這一結論；再次，運用主營業(yè)務利潤率來衡量企業(yè)績效，提出假設并建立回歸模型，得出醫(yī)藥制造業(yè)上市公司創(chuàng)新能力與企業(yè)績效呈正相關，企業(yè)創(chuàng)新能力四大要素對企業(yè)績效產生正面的影響。同時反映醫(yī)藥制造業(yè)上市公司創(chuàng)新能力的10大指標中四大指標（技術人員投入率、全員勞動生產率、國有股占比、銷售人員投入率）與企業(yè)績效關系為負，表明醫(yī)藥制造業(yè)上市公司更應注重這四個方面的投入；最后，依據理論及實證研究，對提升醫(yī)藥制造業(yè)企業(yè)創(chuàng)新能力提出了針對性的建議。
[Abstract]:Pharmaceutical manufacturing industry is an important industry involving national health, social stability and economic development. It is also one of the fastest growing and most competitive industries in the world. With the acceleration of the process of economic opening, how to effectively improve the innovation ability of pharmaceutical manufacturing enterprises, improve the performance of enterprises, and maintain the sustainable development of enterprises, this is undoubtedly an important issue that enterprises need to pay close attention to and solve. The study of the relationship between innovation ability and performance of pharmaceutical manufacturing enterprises is not only of guiding significance to the development of enterprises, but also of reference to the government in formulating relevant policies. This article uses the theory and the demonstration to combine the analysis method, first according to the domestic and foreign related literature and the theory knowledge about the enterprise innovation ability and the performance, has defined the enterprise innovation ability connotation and the medicine manufacturing enterprise innovation ability constituent factor. This paper expounds the internal relations of the four elements of pharmaceutical manufacturing enterprises' innovation ability, that is, marketing innovation ability, management innovation ability, technological innovation ability and institutional innovation ability, and the mechanism of each factor acting on the enterprise performance. Secondly, based on the development situation and industry characteristics of pharmaceutical manufacturing industry, 36 pharmaceutical manufacturing sample enterprises are selected from Shanghai Stock Exchange, and the evaluation index system of innovation ability of listed pharmaceutical manufacturing companies is constructed. The conclusion is that the overall level of innovation ability of listed pharmaceutical manufacturing companies is not high, and the gap between enterprises is large, so we should strengthen the cultivation of innovation ability. Thirdly, the main business profit margin is used to measure the performance of the company, and the hypothesis is put forward and the regression model is established. The conclusion is that the innovation ability of the listed pharmaceutical manufacturing company is positively correlated with the enterprise performance. The four elements of enterprise innovation ability have a positive effect on enterprise performance. At the same time, four of the 10 indexes reflecting the innovation ability of listed companies in pharmaceutical manufacturing industry (technical personnel input rate, total labor productivity, proportion of state-owned shares, investment rate of sales personnel) have negative relationship with enterprise performance. It shows that the listed companies in the pharmaceutical manufacturing industry should pay more attention to the investment in these four aspects; Finally, based on the theoretical and empirical research, some suggestions are put forward to improve the innovation ability of pharmaceutical manufacturing enterprises.
【學位授予單位】：重慶工商大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：F426.72;F273.1

【參考文獻】

相關期刊論文 前10條

1 劉玉來;我國中小企業(yè)技術創(chuàng)新的制約因素及對策[J];北京大學學報;2000年S1期

2 周亞虹;許玲麗;;民營企業(yè)R&D投入對企業(yè)業(yè)績的影響——對浙江省桐鄉(xiāng)市民營企業(yè)的實證研究[J];財經研究;2007年07期

3 孫虹;;我國醫(yī)藥制造業(yè)技術創(chuàng)新相對效率研究[J];科技和產業(yè);2012年03期

4 陳廣宇;張國政;高麗萍;;基于AHP的企業(yè)創(chuàng)新能力相關因素分析[J];工業(yè)技術經濟;2009年10期

5 何建洪;賀昌政;;創(chuàng)新能力與創(chuàng)新型企業(yè)評價研究[J];管理學報;2011年02期

6 陳紅川;;醫(yī)藥制造業(yè)技術創(chuàng)新能力評價實證研究[J];廣州大學學報(自然科學版);2013年04期

7 段福興,張建東,程鈞謨;企業(yè)知識創(chuàng)新能力模糊評價體系研究[J];華東經濟管理;2005年05期

8 王穎;沈月春;;知識管理能力與技術創(chuàng)新能力對企業(yè)績效的協同影響[J];經濟論壇;2008年03期

9 廖理,姜彥福;國有企業(yè)的技術創(chuàng)新、組織創(chuàng)新與制度創(chuàng)新[J];技術經濟;1996年09期

10 馬永紅;趙凌晨;劉拓;;創(chuàng)新型企業(yè)評價體系的構建研究[J];技術經濟;2007年10期

相關博士學位論文 前2條

1 鄒鮮紅;我國醫(yī)藥制造業(yè)技術創(chuàng)新效率及其影響因素研究[D];中南大學;2010年

2 白戈;營銷能力與企業(yè)創(chuàng)新行為關系研究[D];西南財經大學;2010年

本文編號：2429804